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Radiotherapy remains an effective treatment modality in cancer
management, being administered to 50–60% of all patients with
malignant disease. Improvements in the success of radiotherapy
can be expected from better dose prescription and the rational use
of altered fractionation schedules and radiomodifiers and by the
selection of patients for the most appropriate treatment.
Proliferation of tumour clonogens during treatment is thought to
be a major reason for the failure of conventional (6–7 weeks) frac-
tionation schedules to cure some tumours (Withers et al, 1988;
Fowler and Lindstrom, 1992). If tumours that are likely to undergo
rapid repopulation could be identified prior to treatment, reducing
the overall treatment time using accelerated fractionation sched-
ules (Peters et al, 1988; Fowler, 1990; Dische et al, 1997; Horiot 
et al, 1997) might increase the probability of controlling them.
Currently, the use of the halogenated pyrimidines and flow
cytometry (FCM) is considered to be the best method to measure
proliferation rates in vivo as the technique requires only a single
biopsy to measure the potential doubling time (Begg et al, 1985).
However, evidence that the Tpot measurement can predict the
outcome of radiotherapy has still to be established unequivocally
(Begg, 1995). The reasons for this are twofold. Firstly, many of the
studies in which Tpot measurements have been applied to radio-
therapy patients suffer from small patient numbers (Begg et al,
1990; Bourhis et al, 1993; Corvo et al, 1993). Secondly, the 
accuracy and reproducibility of the Tpot measurement may not be
adequate.
In 1992, a cooperative was set up to address these two issues in
a large multicentre study of conventional radiotherapy. The NCI-
sponsored T92-0045 trial consists of 23 European centres, which
set out to accrue 1000 patients in four tumour localizations (head
and neck, rectum, uterine cervix and bronchus); all patients were
treated by conventional radiotherapy and in all cases a pretreat-
ment Tpot measurement was made. To date, over 800 patients have
been entered into the trial.
In this paper, we report on a study of 102 sequential specimens
from 97 patients entered into the trial. Three laboratories have
investigated aspects of sample preparation and analysis to estab-
lish where the major sources of variation exist. We discuss
whether quality control guidelines and a consensus opinion can
increase the reliability and clinical utility of the measurement.
MATERIALS AND METHODS
Patients
Material for the study was selected on a consecutive basis, the only
criterion being that there should be enough tumour material. A
total of 102 specimens were processed and analysed in the three
centres and a single set of disc data, from these same patients, was
analysed in each centre. The specimens consisted of 25 cervix, 36
oral cavity, 35 rectum and six lung tumours originating from 11 of
the participating centres. Each patient had received an intra-
venous injection of 100 mg m–2 iododeoxyuridine (IdUrd) (NCI,
Investigational Drugs Branch, Brussels) several hours prior to the
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Correspondence to: GD Wilsonsurgical procedure. The median time between injection and
surgery was 6.33 h (range 3–10 h, 5.83 and 7.0 h being the 25th
and 75th quartiles).
Sample preparation and staining
The specimens were fixed in ice-cold 70% ethanol for storage.
Prior to the study, each centre agreed on a basic sample prepara-
tion and staining protocol. The fragments of tissue were minced
using scissors and placed in 5 ml of 0.1 M hydrochloric acid
containing 0.4 mg ml–1 porcine trypsin (Sigma, St. Louis, MO,
USA) and incubated at 37°C until the tissue was digested; this was
typically between 45 and 60 min. The resultant nuclei suspension
was filtered through 35-mm nylon mesh and centrifuged at 
2000 r.p.m. for 5 min. The resulting pellet was resuspended in 
2 ml of 2 M hydrochloric acid for 15 min to unwind DNA partially,
allowing monoclonal antibody access to IdUrd. The samples were
then washed twice with 5 ml of phosphate-buffered saline (PBS)
to remove the acid and then resuspended in 0.5 ml of PNT (PBS
containing 0.5% normal goat serum and 0.5% Tween-20) and 
20 ml of mouse anti-5-bromo-2’-deoxyuridine (BrdUrd)/IdUrd
monoclonal antibody (Dako). The tubes were incubated for 1 h at
room temperature in the dark. After washing with PBS, the pellets
were resuspended in 0.5 ml of PNT containing 20 ml of goat anti-
mouse IgG (whole molecule) fluoroscein isothiocyanate (FITC)
conjugate and incubated for 30 min at room temperature. After
washing with PBS, the specimens were resuspended in 1 ml of
PBS containing 10 mg ml–1 propidium iodide.
Flow cytometry
The samples were analysed on FACScan flow cytometers (Becton
Dickinson, San Jose, CA, USA) in each centre. The DNA signal
from propidium iodide was collected into the FL3 channel and cell
doublets discriminated using the width and area signal. The FITC
signal from IdUrd was collected on a logarithmic amplifier in the
FL1 channel. At least 10 000 single events were collected.
Data analysis
Data analysis consisted of three distinct procedures: the decision
as to the ploidy status, the setting of the regions to detect IdUrd
incorporation and the setting of the regions to measure Ts. The
initial decision as to the ploidy status governed the regions that
were used to assess the kinetic parameters. A tumour was consid-
ered diploid if only one stem line of cells could be observed. The
decision as to whether a tumour was diploid or tetraploid was
based on both the proportion of G2/tetraploid G1 cells and the pres-
ence of IdUrd labelling. If significant labelling, distributed in the
expected pattern, was associated with a 4n to 8n population, it was
considered tetraploid irrespective of the proportion of cells. If the
proportion of diploid G2 cells exceeded 15%, then tetraploidy was
classified. The major G1 peak classified aneuploid tumours, but
polyploidy was noted. The decision as to whether a tumour was
hypo- or hyperdiploid was based on which population contained
proliferating cells, i.e. if the first G1 peak showed proliferation this
would be assumed to be the tumour population and the classifica-
tion would be hypodiploid. In some tumours with near-diploid
DNA, it was not possible to analyse the labelled populations 
separately and these represented a category of tumours that were
classified as aneuploid but analysed as diploid.
Figure 1 shows the FCM profiles and regions required for
analysing both a diploid and an aneuploid tumour. After a region
(R1) was set for doublet discrimination on the FL3 area and width
dot plot, a second region (R2) was set on the gated FL3 area and
FL1 dot plot, to discriminate the IdUrd-labelled cells. The lower
limit of this region was set by experience rather than using a
control. The data for LI and Ts were analysed from single-
parameter DNA histograms generated from the total and the
IdUrd-labelled cells only.
In diploid tumours, a total of four markers were set. On the total
DNA profile, M1 and M2 identified the G1 and G2 populations,
respectively, for analysis of Ts. On the IdUrd-labelled DNA
profile, M3 and M4 marked the divided cells and those still
moving through S-phase for correction of the LI and calculation of
Ts respectively. In aneuploid tumours, four further regions were
set. M1 and M2 identified the diploid and aneuploid G1/G0 popula-
tions for calculation of the DNA index, M2 and M3 contained the
G1 and G2 of the aneuploid population and M4 described the total
number of aneuploid cells. In the IdUrd-labelled DNA profile, M5
and M6 were used to correct for cell division in the diploid and
aneuploid population, M7 delineated the population still traversing
S-phase for the calculation of Ts and M8 measured the total
number of aneuploid labelled cells.
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Figure 1 Typical examples of a diploid (A) and aneuploid (B) flow
cytometry profile. The dot plot (left) shows the region delineating BrdUrd-
labelled cells. The histograms (right) show the DNA profile of all single nuclei
(A) and of BrdUrd-labelled nuclei only. See text for description of markersCalculation of DNA index, LI, Ts and Tpot
All data were handled electronically; the numerical information
was imported directly into an Excel spreadsheet from the FCM
analysis program (PC Lysys).
The DNA index was calculated using the ratio of M2/M1 for
aneuploid tumours. The total LI (TLI) was calculated making a
correction for those cells that had divided between injection and
biopsy. For diploid tumours, the calculation was as follows using
the numbers of cells in each of the following regions:
Total labelled cells – M3/2
Total cells – M3/2
In aneuploid tumours the TLI was calculated as:
Total labelled cells – (M5 + M6)/2
Total cells – (M5 + M6)/2
In addition, the corrected LI could be calculated for the tumour
cells only (ALI):
M8 – M6/2
M4 – M6/2
The Ts was calculated using the relative movement method (Begg
et al, 1985) in which the mean DNA content of the G1 and G2
populations and that of the IdUrd-labelled cells, yet to divide, are
required to calculate a parameter termed the relative movement
(RM). The regions used for this are shown below, with the corre-
sponding regions for aneuploid tumours in parentheses.
RM = M4(M7) – M1(M2)
M2(M3) – M1(M2)
The Ts was calculated from the RM using the original assumptions
that the RM at time zero was 0.5 because of the uniform distribution
of labelled cells throughout S-phase and that the value reaches 1.0 at
a time equal to Ts because of uniform progression of labelled cells
through S. The Ts was simply calculated from the relationship:
Ts =
0.5 ´ t (time between injection and biopsy)
RM – 0.5
The Tpot was computed from the Ts and the LI using the formula
of Steel (1977)
Tpot =
l´Ts
LI
where l is a correction factor for the age distribution of the popu-
lation and was assumed to be 0.8.
Statistical analysis
A variety of statistical tests were applied, including linear regres-
sion analysis, Spearman’s rho, k measure of agreement and
Bland–Altman methods for assessing agreement (Bland and
Altman, 1986). Statistical analyses were carried out using JMP
(SAS Institute, Cary, NC, USA).
RESULTS
Initial characterization of the data set
Table 1 summarizes the cell kinetic parameters obtained for the
complete set of samples in each of the three centres. The nomen-
clature was such that the first letter represented the centre where
the sample was processed and the second letter indicated where the
sample was analysed; thus, LG signifies that the sample was
processed in Lausanne and analysed in the Gray Laboratory.
Considerable variation was present within and between data sets.
The most notable discrepancies were the differences between the
median and mean values for Ts, indicating a non-symmetric distri-
bution. This was particularly evident within the single data set
analysed by all three centres in which the standard deviations were
greater than those in samples processed separately in each centre.
This variability was translated into the data for Tpot, which showed
significant differences between the data sets.
The underlying reason for this result was the presence of spuri-
ously high Ts values within some of the disc analysis data sets and
which were not reciprocated within the sample data set. In one
specimen, an extreme value of 1432 h was calculated for Ts in one
centre in comparison with 14.1 and 61.1 h from the other two
centres. This was a particularly difficult and confusing profile to
analyse and, of the 102 specimens, there were 12 in which either
one or two of the centres recorded Ts values that were considered
to be spuriously high (> 40 h). Censoring of these data resulted in
better agreement between mean and median values for Ts and Tpot
(Table 1) but was without effect on LI.
Spearman rank correlation analysis
The true test of the Tpot measurement is whether the estimated
values are reproducible between different observers and different
centres in the ranking of tumours as fast or slow. Table 2 demon-
strates that the major discrepancies in the single data set reside
within the calculation of Ts as evidenced by the low correlation
coefficients for both RM and Ts. The agreement in determining the
total LI was consistently high between all observers. The agree-
ment in calculating the aneuploid LI was less precise and, as will
be discussed later, was primarily due to interpretation of the DNA
profile. Tpot relies on both the LI and Ts and, as a result, the agree-
ment for this parameter was intermediate among that found for its
determinants. However, the agreement was improved considerably
by censoring the specimens with outlying Ts values. The level of
concordance in Tpot between the three centres resulted in correla-
tion coefficients ranging from 0.78 to 0.86.
The correlation coefficients when samples were processed and
analysed in different centres fell dramatically for all parameters.
The loss of agreement might result from variability in sample
processing, staining and running and from tumour heterogeneity.
Consideration of the LI data would appear to suggest that the LI
might be the major determinant. The level of agreement was better
for the aneuploid LI than for the total LI, the reverse of the disc
data. Within a specimen, it is likely that the LI of the tumour cells
alone might be more consistent between different areas than the
total LI, which includes stromal and infiltrating cells. The correla-
tion for Ts was only slightly worse than for the disc data. The
combination of these two parameters resulted in correlation
coefficients of 0.30–0.45 for Tpot irrespective of whether the
complete or restricted data sets were considered. The disc and
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data sets resulted in correlation coefficients similar to those seen
within the sample comparison.
Kappa statistic analysis
The kappa correlation (k) was chosen to measure the degree of
agreement between samples. In this analysis, each parameter was
classified according to whether it was above or below the median
value for each individual data set, and the results for LI, Ts and Tpot
are shown in Table 3. The data reiterate the findings of the
Spearman’s analysis. In the disc-only data, the level of agreement
in TLI was excellent (> 0.8), Tpot was in the good category
(0.61–0.8) and the Ts values fell into the moderate category of
agreement (0.41–0.6). In the sample and the disc–sample data, the
majority of k values fell below 0.5, which indicated poor 
agreement.
Bland–Altman analysis of agreement
The level of agreement was assessed using the procedure of Bland
and Altman. The data are presented in Table 4 for TLI, Ts and Tpot
for the restricted data set of 90 patients. The mean difference gives
an indication of measuring bias in each data set and centre and two
standard deviations defines the limits within which the differences
would be expected to be found. Within the complete (data not
shown) and censored data set, the TLI shows excellent agreement
in the disc data, with mean differences of less than 0.1%. The 95%
confidence intervals on the mean difference were no more than 
± 0.3% around the mean value. The majority of differences would
be found within ± 4.0% of the mean. However, within the sample
and sample/disc data sets, the mean difference ranges from –2.0%
to 3.9% and the standard deviations increased to between 5% and
6.0%. This would result in wide expected limits of agreement of 
± 10–12% around the mean.
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Table 1 Summary of kinetic parameters obtained from each centre for all 102 specimens. The numbers in parentheses
represent the data obtained from 90 patients excluding the censored Ts data
LL LB LG BB GG
TLI
Median 0.094 0.093 0.093 0.105 0.073
Mean 0.104 0.110 0.102 0.118 0.083
s.d. 0.060 0.110 0.055 0.070 0.051
ALI
Median 0.186 0.166 0.180 0.194 0.119
Mean 0.200 0.204 0.195 0.217 0.131
s.d. 0.103 0.158 0.098 0.131 0.076
Ts
Median 14.2 (13.4) 13.7 (13.1) 11.7 (11.5) 11.3 (11.1) 10.9 (10.7)
Mean 20.0 (14.9) 32.1 (14.8) 14.0 (12.9) 12.7 (11.8) 11.8 (11.5)
s.d. 22.6   (5.6) 141.1 (6.0) 10.4   (5.2) 6.0   (3.4) 4.4   (4.3)
Tpot
Median 3.8 (3.6) 4.2 (4.2) 3.3 (3.4) 2.9 (2.8) 4.0 (4.1)
Mean 5.8 (5.4) 9.8 (6.7) 4.3 (4.2) 5.2 (4.4) 5.2 (5.3)
s.d. 6.1 (5.6) 32.5 (10.4) 3.2 (2.8) 8.2 (5.4) 4.0 (4.1)
Table 2 Spearman’s rank correlation coefficient analysis. Data are presented for all specimens and for 90
cases excluding the outlying Ts values. All of the combinations were significantly correlated, except for the
RM data for the comparison of BB and GG. In this data set, a correlation coefficient of 0.34 results in
P-value < 0.0001
Parameter Sample Disc Disc/sample
LL LL BB LL LL LB LB LG
BB GG GG LB LG LG BB GG
RM (102) 0.44 0.50 0.13 0.63 0.50 0.36 0.35 0.40
(90) 0.50 0.51 0.19 0.63 0.60 0.42 0.34 0.46
TLI (102) 0.50 0.49 0.53 0.94 0.95 0.95 0.48 0.48
(90) 0.53 0.50 0.60 0.94 0.96 0.96 0.50 0.50
ALI (102) 0.65 0.55 0.59 0.91 0.83 0.87 0.61 0.58
(90) 0.68 0.49 0.61 0.91 0.85 0.86 0.64 0.58
Ts (102) 0.49 0.50 0.37 0.69 0.50 0.46 0.43 0.55
(90) 0.50 0.47 0.40 0.63 0.61 0.51 0.44 0.63
Tpot (102) 0.36 0.30 0.36 0.82 0.61 0.59 0.49 0.24
(90) 0.45 0.31 0.43 0.84 0.86 0.78 0.47 0.30The data for Ts indicate variable agreement in both the disc and
sample data, with the mean differences ranging from –3.3 to 1.9 h.
There was a trend for both Besancon and the Gray Laboratory to
produce lower Ts values than Lausanne. The important parameter
is the standard deviation, which varies between 4 and 6 h for each
combination, indicating that observers or centres could differ by as
much as ± 12 h from the mean value. The variability in Ts was
translated into differences in Tpot. Within the restricted data set, the
mean differences were reduced to ± 2 days and the limits of agree-
ment ranged from 4 to 10 days around the mean.
The influence of DNA ploidy
The analysis of Tpot is dependent on the classification and interpre-
tation of the DNA profile. In the complete data set, 34 tumours
were classified as diploid and 20 were classified as aneuploid
(with the same DNA index) by all observers and centres; these
represent 53% of the specimens. A further five specimens were
uniformly classified as aneuploid but with some discrepancy in the
DNA index values. In a further 25 specimens, four out of the five
combinations agreed on either an aneuploid (18 cases) or a diploid
(seven cases) profile. The majority of these discrepancies (22
cases) arose within the sample data. To examine the influence of
DNA ploidy, the disc data and sample data sets were analysed
separately to establish which factors were attributable to observer
variation alone and which to observer and sampling variation.
Disc data set
Forty-two specimens were agreed as diploid and 41 were
uniformly classified as aneuploid with similar DNA indices,
representing 81% of the data set. The discrepant tumours were
eight in which two observers classified the specimen as aneuploid
and the other reported a diploid profile and six in which two
diploid values were recorded and one aneuploid. One specimen
had three different aneuploid values, three specimens had two
similar aneuploid indices and one discrepant and one specimen
was classified as diploid, hyperdiploid and hypodiploid. In the
restricted data set (90 specimens), 42 specimens were diploid, 34
were uniformly aneuploid, six were classified as aneuploid by two
observers and diploid by the other and five were classified as
diploid by two observers and aneuploid by the other. Only three
specimens did not fit into these classifications. It was noted that
the 12 specimens excluded from the censored data set were either
aneuploid or discrepant cases.
Table 5 summarizes the improvement in agreement when
consensus on ploidy was reached. The agreement in TLI was
further increased to a coefficient of, on average, 0.97 while ALI
coefficients exceeded 0.9. There was a significant increase in
agreement in Ts compared with the data in Table 2; the coefficients
reached 0.8 for diploid tumours and 0.6–0.7 for aneuploid
tumours. These improvements in agreement in LI and Ts were
translated into an increase in the correlation coefficients for Tpot,
with values of 0.9 overall in the restricted data set. Again, agree-
ment was better in diploid tumours (0.94) than that obtained in
aneuploid specimens.
Sample data
Ploidy agreement in the sample data set was worse than that found
within the disc data set. In the 102 samples, 38 were classified as
diploid by all three centres but only 21 were aneuploid with the
same DNA index; this represents 58% of specimens. In a further
11 specimens, two diploid and one aneuploid classifications were
recorded and, in 18 cases, two similar aneuploid values and one
diploid were obtained. The rest consisted of seven cases in which
there were two different aneuploid values accompanying one
diploid, five cases with two similar aneuploid values with a
different aneuploid DNA index and two cases with three different
aneuploid indices.
Table 6 summarizes the correlation data obtained after ploidy
agreement in the sample data. It can be seen (in comparison with
Table 2) that there is some improvement in the correlation coeffi-
cients for TLI, Ts and Tpot. This result was more evident in the
complete data set rather than in the censored data set, as most of
the censored data were due to aberrations in the disc data. Unlike
the disc data (Table 5), the improvement in correlation for Tpot was
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Table 3 Kappa correlation analysis using the median value as a cut-off for each parameter in each data set
Parameter Sample Disc Disc/sample
LL LL BB LL LL LB LB LG
BB GG GG LB LG LG BB GG
TLI (102) 0.47 0.33 0.45 0.92 0.92 0.92 0.45 0.29
(90) 0.38 0.33 0.38 0.82 0.82 0.96 0.29 0.33
Ts (102) 0.49 0.33 0.29 0.65 0.45 0.49 0.41 0.45
(90) 0.51 0.33 0.38 0.69 0.56 0.57 0.42 0.51
Tpot (102) 0.37 0.18 0.22 0.81 0.65 0.69 0.37 0.14
(90) 0.37 0.22 0.22 0.78 0.73 0.78 0.38 0.38
Table 4 Bland–Altman analysis of the agreement between centres for the
restricted data set (90) specimens. The data represent the mean difference
and standard deviation for each pair of observer and centre combinations
Centres TLI (%) Ts (h) Tpot (days)
Mean s.d. Mean s.d Mean s.d
BBGG 3.9 5.7 0.25 4.16 –0.83 6.29
BBLL 1.9 6.0 –3.05 5.16 –0.95 6.60
GGLL –2.0 5.4 –3.30 4.93 –0.12 6.36
LBLG –0.1 1.6 1.94 6.61 2.48 8.71
LBLL –0.1 2.0 0.0002 5.04 1.34 5.19
LGLL –0.03 1.4 –1.94 4.44 –1.14 4.09
BBLB 2.0 6.2 –3.05 5.64 –2.29 10.37
GGLG –2.0 5.1 –1.37 3.88 1.03 4.03not superior in diploid compared with aneuploid tumours,
although the correlation coefficients for Ts were superior in
the diploid group. The correlation coefficients for TLI, Ts and
Tpot were not dissimilar to each other, with average values
ranging from 0.5 to 0.7, but agreement was generally better in TLI
than in Ts.
Proliferative classification using cut-off values
The ultimate requirement of the Tpot measurement will be to clas-
sify tumours as fast or slow with some degree of certainty. In this
analysis, the LG data were considered to be the ‘true’ data and the
others compared with this. Figure 2 shows the data plotted as a
ratio of the median LG value (3.44 days) for the restricted data set.
The data in the upper left and lower right quadrants indicate the
misclassified measurements. LL would wrongly classify 10% as
fast and 12% as slow; for LB it would be 18% and 8%, GG 22%
and 9% and BB 4% and 9%.
DISCUSSION
In order to use a FCM measurement in clinical practice for the
potential selection of patients for more appropriate treatment
schedules, the sources of variation within the technique need to be
understood and minimized. In common with all FCM-based
methods there will be variation among centres associated with
differences in instrumentation and laboratory techniques. Some of
these can be minimized by using the same model of flow
cytometer, agreed machine set-up and standardized laboratory
procedures. This will leave the main source of variation to be
attributable to what has been termed the interaction component.
This comprises sample heterogeneity and inconsistencies in
sample preparation, staining and analysis. If Tpot values are to be
meaningful and reproducible within and between laboratories,
then this variation must be eliminated or minimized otherwise the
technique will not be transportable or the data interchangeable.
The measurement of Tpot from a single sample represents a rela-
tively complex FCM procedure, many aspects of which have the
potential to introduce variation (Terry and Peters, 1995). These
include the sample itself, the tissue digestion with pepsin, the
staining procedure (particularly the denaturation step), the inter-
pretation of the DNA profile and the region setting for relative
movement and labelling index analysis. Against this background,
either the methodology must be robust or the tolerance limits of
the measured parameter must be wide enough to permit some vari-
ation without compromising the clinical significance of the ulti-
mate value. The NCI T92–0045 study was designed to address
these two issues firstly with the comparisons reported here and,
secondly, with the ultimate application of the measured values,
with detailed knowledge of their variation, to the clinical data.
Tpot reproducibility has been the subject of three previous
reports (Wilson et al, 1993a; Haustermans et al, 1995; Tsang et al,
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Table 5 Spearman’s correlation analysis of disc specimens in which there was consensus in ploidy
classification. ‘All’ refers to that which were uniformly classified as diploid or aneuploid with the same DNA index
and ‘dip’ and ‘aneu’ refer to the subgroups of diploid or aneuploid tumours only
Parameter LB vs LG LB vs LL LG vs LL
All Aneu Dip All Aneu Dip All Aneu Dip
TLI (102) 0.97 0.96 0.96 0.96 0.94 0.98 0.96 0.95 0.97
(90) 0.97 0.98 0.97 0.95 0.97 0.97
ALI (102) 0.97 0.90 0.89
(90) 0.98 0.90 0.92
Ts (102) 0.59 0.36 0.79 0.80 0.74 0.83 0.64 0.37 0.77
(90) 0.67 0.58 0.77 0.70 0.75 0.71
Tpot (102) 0.73 0.48 0.94 0.84 0.71 0.93 0.74 0.56 0.94
(90) 0.88 0.72 0.90 0.76 0.93 0.88
Table 6 Spearman’s correlation analysis of sample specimens in which there was consensus in ploidy
classification. ‘All’ refers to tumours that were uniformly classified as diploid or aneuploid with the same DNA
index and ‘dip’ and ‘aneu’ refer to the subgroups of diploid or aneuploid tumours only
Parameter BB vs GG BB vs LL GG vs LL
All Aneu Dip All Aneu Dip All Aneu Dip
TLI (102) 0.66 0.69 0.69 0.63 0.66 0.58 0.63 0.68 0.63
(90) 0.60 0.57 0.68 0.53 0.50 0.55 0.50 0.42 0.63
ALI (102) 0.68 0.68 0.71
(90) 0.61 0.68 0.49
Ts (102) 0.42 0.38 0.54 0.57 0.45 0.63 0.69 0.42 0.69
(90) 0.40 0.31 0.64 0.51 0.47 0.64 0.50 0.33 0.71
Tpot (102) 0.53 0.55 0.55 0.59 0.66 0.52 0.49 0.58 0.52
(90) 0.43 0.40 0.54 0.45 0.42 0.51 0.31 0.26 0.521995), which were restricted to two-centre analysis. The same
general conclusions were reached in these studies, namely that the
estimation of Ts is the major source of analytical variation and that
sample processing and tumour heterogeneity account for the vari-
ation between centres.
In this present multicentre study, we found the measurement of
LI to be robust and reproducible in the disc data, with
Bland–Altman analysis revealing no evidence of any systematic
errors, as was found in one of the previous studies (Haustermans 
et al, 1995). Correlation analysis, both Spearman’s and kappa,
showed a high level of agreement among observers. Concordance
of absolute values was extremely high, with linear regression
analysis resulting in slopes of greater than 0.9 and intercepts of
less than 0.01 (data not shown) for all three combinations. Indeed,
if the LI was used to rank tumours according to their proliferative
characteristics, only two specimens would be classified wrongly
as fast and two as slow using this data set. The measurement of LI
is a relatively simple procedure requiring only two regions.
However, the first region, which delineates the IdUrd-labelled
cells, is set subjectively and has received some criticism and
discussion (White and Terry, 1992). The data in this study would
suggest that fitting a distribution to the unlabelled G1 and G2 popu-
lations, in the IdUrd dot plot, and using standard deviations to set
the lower limit of detection is unwarranted.
The estimation of Ts was problematical. The analysis depends
on the same initial region to delineate the IdUrd-labelled cells
(which has been shown above to be reproducible) and a further
three regions to measure the mean DNA content of G1 and G2 and
of the IdUrd-labelled cells which have not divided. This should be
a relatively straightforward procedure (as described in Figure 1)
but is subject to the complexity of the IdUrd–DNA distribution.
Twelve specimens were classified as outliers with the common
feature of a Ts value that was considered unreasonable, either too
long (11 specimens) or too short (one specimen). All 12 specimens
were classified as aneuploid by one or more observers, and 8 of the
12 specimens had discrepancies in the ploidy value. The majority
of these specimens (11 cases) had low RM values of between 0.5
and 0.6 caused by multiploid DNA and the selection of the wrong
G1 or G2 peak in the DNA profile for the RM calculation. It has
been suggested that the ratio of G2 to G1 should be considered
constant such that only the mean G1 need be calculated (Begg et al,
1988). This procedure improves the correlation in the Ts in the disc
data but is without effect in the sample data.
The inconsistencies in region setting were highlighted by the
section dealing with concordance in DNA ploidy prior to evalua-
tion of the Ts. Indeed, even when all observers agreed that the
profile was diploid, the correlations in Ts failed to reach a value
greater than 0.8. Analysis of the raw data in those diploid tumours
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Figure 2 Comparison of Tpot values obtained from each centre and observer. The data are expressed as the ratio of the median value
(3.44 days) from the LG restricted data set. The quadrants segregate the data into those which agree on a fast or slow classification (lower
left and upper right) and those which disagree (upper right and lower left). The symbols represent BB (n n), GG (◊ ), LB (l l) and LL (∆ )that failed to correlate revealed that there was very good agree-
ment in the mean values for the G1 population but discrepancies in
the measured mean DNA values for G2 and the region defining the
IdUrd-labelled cohort. The discrepancy in G2 can arise from the
tightness of the computer-generated region, which is dependent on
the definition of the peak. The RM region is dependent on the
tightness of the G1 region and whether or not it has been set juxta-
posed to this region (see Figure 1).
In aneuploid tumours that were ascribed the same DNA index
by all observers, the correlation coefficients reached only 0.6 to
0.7 for Ts. The underlying reason for this was again variation in the
region delineating the IdUrd-labelled cohort and to a lesser extent
the G2 population. The discrepancies with the former arose
because of the presence of the diploid S and G2 populations within
the RM window. In some instances, the observers had attempted to
eliminate them from the measurement by setting the lower limit of
the analysis window to the right-hand side of the diploid G2 rather
than juxtaposed to the aneuploid G1. This procedure is acceptable
only if the IdUrd-labelled cohort of the aneuploid population has
clearly progressed through S-phase, such that it is distinguishable
from the diploid labelled population.
Although Ts was the dominant feature in introducing variability
into the agreement in the Tpot measurement, the LI determines the
extent of intrinsic variation in Tpot. This is primarily due to the
broader distribution of potential values (40-fold variation) for LI
compared with Ts (eight-fold variation). To some extent, the repro-
ducibility of LI overcomes the inherent problems within the Ts
estimation to produce excellent correlation coefficients for Tpot
once outliers and ploidy agreement are taken into account (0.9 or
greater). In the disc data set, this cohort represented 75% of the
original number of specimens analysed.
The sample data presents problems that have wider implications
for the utility of Tpot as a predictive measurement. The sample data
were subject to all forms of potential variation and introduced the
component due to sample processing and tumour heterogeneity.
Tables 2 and 6 demonstrate that the correlation between all three
centres is drastically reduced, compared with the disc data, for
each of the parameters in the Tpot measurement. Correlation
analysis yielded values of no greater than 0.5–0.6 after accounting
for ploidy differences; this comparison also introduced the greatest
errors in the previous two reports of Tpot reproducibility (Wilson et
al, 1993a; Haustermans et al, 1995).
It was not possible to design this study to distinguish between
sample processing and tumour heterogeneity because of the limita-
tions of tissue. Clues from the data suggest that heterogeneity may
be the dominant feature and thus a common problem to all biopsy-
based measurements. In particular, the correlation for aneuploid LI
exceeded that for total LI within the sample data, which is the
converse of the disc data. The explanation for this reversal may
reside within the consideration of genotypic and phenotypic
heterogeneity within solid tumours (Shackney and Shankey,
1995). Tumour growth is determined by proliferation, differentia-
tion and cell death, each of which is genetically controlled but
subject to microenviromental stimuli such as nutrient and oxygen
deprivation. Proliferative heterogeneity between samples from the
same tumour will certainly arise as a function of differentiation,
tumour growth pattern, host cell infiltration and vascular perfu-
sion. Each of these will cause areas of microregional variation in
the percentage of proliferating and non-proliferating cells and in
the ratio of tumour cells to normal cells. The aneuploid LI is
subject to the genotypic and phenotypic variability induced by
differentiation, growth patterns and tumour perfusion. However,
the total LI reflects the influence of both normal and tumour cells
and may be also affected, to a greater extent, by heterogeneity due
to variation in host cell content.
The mean intratumoral coefficient of variation (CV) of the three
samples processed and analysed in each centre was 49% for Tpot.
This was less than the 63% reported in the largest study of intra-
tumour variability in Tpot (Wilson et al, 1993b) in which six biop-
sies from 30 colorectal tumours were studied. In the colorectal
study, CVs of 28% and 36% were reported for LI and Ts compared
with 38% and 27% in this present study. These data demonstrate
that both Ts and LI are important variables and can introduce vari-
ability into the ultimate Tpot measurement. As has been found in
other studies (Begg et al, 1988; Bennett et al, 1992; Wilson et al,
1993a), the intertumour variation in Tpot, 127% in this present
study, far outweighs the intratumour variability. This indicates
that, despite heterogeneity, proliferation differences between
tumours should be detectable.
This present study demonstrates that significant differences
exist between laboratories in the measurement of Tpot and that
these could result in misclassification of tumours as fast or slow by
one or other centre. The following recommendations can minimize
the analytical and processing errors but heterogeneity is inherent
to the biology of individual tumours.
(1) Dissociation of the specimen into nuclei can introduce
potential errors, particularly if underdigested (Terry and
Peters, 1995). It is important to maximize the yield, in indi-
vidual tumours, to increase the chance of obtaining a repre-
sentative sample. The timing of dissociation should be
adjusted for individual specimen needs, and it is not satisfac-
tory to use a constant time interval for all tumours.
(2) Staining procedures should be standardized to that recom-
mended by a laboratory with experience and the quality
assessed by intercomparison of samples.
(3) Machine conditions should be standardized, although this
will be different for different machines. Doublet discrimina-
tion should be used, the FITC signal should be collected
with log amplification and at least 10 000 events should be
recorded. The last is only a guideline as, for each sample, a
significant number of events in the regions of interest need
to be collected.
(4) Interpretation of the DNA profile should follow the guide-
lines already suggested (Shackney et al, 1993). Aneuploid
populations should not be considered if they represent < 5%
of the specimen unless the IdUrd staining can aid in their
identification. All specimens of near-diploid DNA should be
regarded as hyperdiploid unless the proliferating cells are
clearly seen to emanate from the peak with less DNA. In
near-diploid DNA profiles it will not always be possible to
analyse the aneuploid population separately and all tumours
should be analysed as a single population.
(5) In tumours with multiple DNA peaks, the choice of which
aneuploid population to analyse should be based firstly on
the magnitude of the population and, secondly, on the distri-
bution of IdUrd labelling. The largest population would
normally be analysed unless more proliferation was associ-
ated with a minor peak; this may well be the evolving clone
of the tumour. The G1/G2 ratio should always be checked to
ensure that regions have been set around the appropriate
population.
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of cell division in the time between injection and biopsy.
This may well be a function of the time interval, which
should not be less than 4 h.
(7) Tpot should not be analysed in profiles in which the region of
interest is significantly impeded by overlapping cell popula-
tions from the diploid component or other aneuploid clones.
It is not possible to set strict guidelines to this potential 
artefact, and this should be gained by experience or with
reference to profiles obtained by other expert researchers.
(8) The regions to measure LI and Ts should be as described in
Figure 1, with the tightness of the G1 and G2 regions being
determined by the CV of the corresponding peaks. Cell cycle
analysis of the DNA profile may represent a better method
of assessing the mean DNA contents of G1 and G2 and
should be carried out if possible. The RM window should be
set juxtaposed to the G1 region, except in aneuploid tumours
in which the labelled population has clearly progressed
through its S-phase to a value greater than the diploid G2.
(9) The transcription of data should be electronic to avoid errors.
(10) The calculation of Tpot has been carried out using the Begg
algorithm in this study, but several other alternatives give
different absolute values of Tpot but similar ranking of
tumours (White et al, 1990). The clinical significance of
each derivation of Tpot will be assessed in the final
correlation of the measurement with clinical outcome in
T92-0045 trial.
(11) The question of heterogeneity can only be tackled by
obtaining a large specimen and assessing at least two, and
more if possible, areas from the sample. This may not
always be possible and the quality of the nuclei suspension
becomes crucial to ensure that it is representative. Whatever
the sample, it should always be accompanied by histological
assessment to ensure that a tumour is present and to give
insight into the composition of the specimen.
The overall conclusion from this intercomparison is that agree-
ment can be reached on the measurement of Tpot in at least 75% of
specimens by different observers analysing the same data.
However, in a multicentre study, processing and analysis should be
restricted to a single centre of excellence for the most consistent
results. This does not preclude the interinstitutional comparison of
results as long as the potential errors are clearly understood.
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